Corporate Profile

HCW Biologics is a clinical-stage company advancing the development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.

HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.

 

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings
Filing date Description Form
D

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS

UPLOAD

UPLOAD

Registration statement for face-amount certificate companies

S-1

CORRESP

CORRESP

CORRESP

CORRESP

UPLOAD

UPLOAD